ACRS — Aclaris Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1557746 ·
Last close
$3.38
Market Cap
$536.11M
52W High
$6.60
52W Low
$2.34
ADV30
3,335,158
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 1,629,000 176,000 -23,938,000 -21,505,000 179,693,000 19,167,000 55,112,000
Mar 2026 1,996,000 208,000 -22,192,000 -19,824,000 198,720,000 28,660,000 55,071,000
Dec 2025 1,295,000 -174,000 -22,334,000 -19,795,000 160,460,000 19,960,000 57,378,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,059,000
Investing CF
$3,530,000
Financing CF
$52,294,000
CapEx
$-118,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,009,113,000
Inventory
—
Receivables
$4,680,000
ST Investments
$72,389,000
EBIT TTM
$-85,513,000
Pretax Income TTM
$-75,738,000
Interest Exp TTM
—
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,219,000
EBITDA
$-85,525,000
Free Cash Flow
$-41,970,624
Enterprise Value
$451,985,920
Total Cash
$91,556,000
Total Debt
$1,850,000
Shares Out
158,612,149
Trailing EPS
$-0.59
Book Value
$0.85
ROE
-59.1%
ROA
-29.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,826,000 -74,075,000 -64,923,000 160,460,000 57,378,000 103,082,000 -47,113,000
Dec 2024 18,720,000 -52,527,000 -132,065,000 220,327,000 64,773,000 155,554,000 -20,075,000
Dec 2023 31,249,000 -116,314,000 -88,481,000 197,405,000 40,226,000 157,179,000 -78,325,000
Dec 2022 29,752,000 -85,154,000 -86,908,000 254,596,000 56,975,000 197,621,000 -67,567,000

TTM Snapshot

Revenues TTM
$8,219,000
NetIncome TTM
$-75,738,000
OpCashFlow TTM
—
Assets (Latest)
$179,693,000
Forward EPS
$-0.72

Max Pain — expiry 2026-12-18

max pain strike: $3.00 · spot: $3.50 · call oi: 7,290 · put oi: 2,407
Expected Move to 2026-12-18: ±$0.68 (19.29%) — implied range $2.83 – $4.17 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HELP Helus Pharma Inc. $526.03M $7.20 —
EVO Evotec SE $525.98M $1.48 —
AVBP ArriVent BioPharma, Inc. $552.92M $10.69 —
ANL Adlai Nortye Group Ltd. $556.80M $9.48 —
ZVRA ZEVRA THERAPEUTICS, INC. $559.34M $9.40 —

News headlines (Yahoo Finance, 1h cache)

Aclaris stock falls after atopic dermatitis trial fails
2026-11-16 16:52 · Yahoo
Aclaris Therapeutics’ mAb fails in Phase II eczema trial
2026-11-16 14:58 · Yahoo
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
2026-11-16 14:27 · Yahoo
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
2026-11-16 08:30 · Yahoo
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
2026-11-16 08:28 · Yahoo
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-11-12 12:30 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 13:35 · Yahoo
Aclaris: Q3 Earnings Snapshot
2026-11-05 12:15 · Yahoo
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
2026-11-05 11:59 · Yahoo
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
2026-10-27 22:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.